GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elite Pharmaceuticals Inc (OTCPK:ELTP) » Definitions » Cyclically Adjusted PB Ratio

Elite Pharmaceuticals (Elite Pharmaceuticals) Cyclically Adjusted PB Ratio : (As of May. 19, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Elite Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Elite Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Elite Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elite Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Elite Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Elite Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Elite Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elite Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Elite Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Elite Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Elite Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Elite Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.046/129.4194*129.4194
=0.046

Current CPI (Dec. 2023) = 129.4194.

Elite Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 -0.145 99.695 -0.188
201406 -0.149 100.560 -0.192
201409 -0.094 100.428 -0.121
201412 -0.050 99.070 -0.065
201503 -0.055 99.621 -0.071
201506 -0.023 100.684 -0.030
201509 -0.030 100.392 -0.039
201512 -0.088 99.792 -0.114
201603 -0.047 100.470 -0.061
201606 -0.042 101.688 -0.053
201609 0.025 101.861 0.032
201612 0.029 101.863 0.037
201703 0.028 102.862 0.035
201706 0.005 103.349 0.006
201709 0.008 104.136 0.010
201712 0.008 104.011 0.010
201803 0.006 105.290 0.007
201806 0.004 106.317 0.005
201809 0.002 106.507 0.002
201812 0.000 105.998 0.000
201903 -0.003 107.251 -0.004
201906 -0.002 108.070 -0.002
201909 -0.004 108.329 -0.005
201912 -0.006 108.420 -0.007
202003 -0.004 108.902 -0.005
202006 -0.003 108.767 -0.004
202009 0.014 109.815 0.016
202012 0.016 109.897 0.019
202103 0.016 111.754 0.019
202106 0.018 114.631 0.020
202109 0.020 115.734 0.022
202112 0.023 117.630 0.025
202203 0.025 121.301 0.027
202206 0.025 125.017 0.026
202209 0.027 125.227 0.028
202212 0.030 125.222 0.031
202303 0.029 127.348 0.029
202306 0.030 128.729 0.030
202309 0.044 129.860 0.044
202312 0.046 129.419 0.046

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Elite Pharmaceuticals  (OTCPK:ELTP) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Elite Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Elite Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Elite Pharmaceuticals (Elite Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
Executives
Mark N Pellegrino officer: CFO, Secretary, Treasurer 165 LUDLOW AVE, NORTHVALE NJ 07647
Kirko Kirkov officer: Chief Commercial Officer 165 LUDLOW AVE, NORTHVALE NJ 07647
Chen Robert C J officer: CFO, Secretary, Treasurer 165 LUDLOW AVENUE, NORTHVALE NJ 07647
Marc Bregman officer: CFO, Secretary, Treasurer C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVENUE, NORTHVALE NJ 07647
Eugene M Pfeifer director C/O ELITE PHARMACEUTICALS, INC, 165, NORTHVALE NJ 07647
Davis S Caskey director C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVE, NORTHVALE NJ 07647
Jerry Treppel director 93 SETON HIGHLANDS, PLYMOUTH MA 02360
Mikah Pharma, Llc 10 percent owner 165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Plassche officer: Executive VP of Operations 165 LUDLOW AVE., NORTHVALE NJ 07647
Jeenarine Narine director, 10 percent owner C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Ashok G Nigalaye director, 10 percent owner, officer: Chief Scientific Officer C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Epic Pharma Llc 10 percent owner 227-15 NORTH CONDUIT AVE, LAURELTON NY 11413-3134
Epic Investments, Llc 10 percent owner 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Nasrat A Hakim director, 10 percent owner, officer: President & CEO C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVE., NORTHVALE NJ 07647
Jeffrey A Whitnell director C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVENUE, NORTHVALE NJ 07647

Elite Pharmaceuticals (Elite Pharmaceuticals) Headlines

From GuruFocus